- Home
- ARL vs LYEL Comparison
ARL vs LYEL Comparison
Compare ARL & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- LYEL
- Stock Information
- Founded
- ARL 1999
- LYEL 2018
- Country
- ARL United States
- LYEL United States
- Employees
- ARL N/A
- LYEL N/A
- Industry
- ARL Building operators
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- LYEL Health Care
- Exchange
- ARL Nasdaq
- LYEL Nasdaq
- Market Cap
- ARL 233.2M
- LYEL 207.7M
- IPO Year
- ARL N/A
- LYEL 2021
- Fundamental
- Price
- ARL $14.52
- LYEL $9.84
- Analyst Decision
- ARL
- LYEL Sell
- Analyst Count
- ARL 0
- LYEL 2
- Target Price
- ARL N/A
- LYEL $15.00
- AVG Volume (30 Days)
- ARL 3.9K
- LYEL 148.8K
- Earning Date
- ARL 08-07-2025
- LYEL 08-06-2025
- Dividend Yield
- ARL N/A
- LYEL N/A
- EPS Growth
- ARL N/A
- LYEL N/A
- EPS
- ARL N/A
- LYEL N/A
- Revenue
- ARL $48,234,000.00
- LYEL $65,000.00
- Revenue This Year
- ARL N/A
- LYEL N/A
- Revenue Next Year
- ARL N/A
- LYEL N/A
- P/E Ratio
- ARL N/A
- LYEL N/A
- Revenue Growth
- ARL N/A
- LYEL N/A
- 52 Week Low
- ARL $9.43
- LYEL $7.65
- 52 Week High
- ARL $22.77
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- ARL 57.31
- LYEL 52.64
- Support Level
- ARL $13.22
- LYEL $9.11
- Resistance Level
- ARL $15.00
- LYEL $10.41
- Average True Range (ATR)
- ARL 0.59
- LYEL 0.61
- MACD
- ARL 0.01
- LYEL 0.04
- Stochastic Oscillator
- ARL 77.51
- LYEL 70.77
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.